# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Epstein Barr Virus, Chronic

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 11-20 of 20 results.
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Status: Recruiting
Last Changed: Feb 25, 2020
First Received: Jul 22, 2008
Disease(s): Acute Biphenotypic Leukemia, Acute Myeloid Leukemia in Remission, Ann Arbor Stage I Burkitt Lymphoma, Ann Arbor Stage I Non-Hodgkin Lymphoma, Ann Arbor Stage II Burkitt Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Plasma Cell Myeloma, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Burkitt Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Burkitt Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, High Risk Acute Myeloid Leukemia, Refractory Anemia
Intervention(s): Cyclophosphamide, Cyclosporine, Double-Unit Umbilical Cord Blood Transplantation, Fludarabine, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Thiotepa
Locations: University of Colorado Hospital, Aurora, Colorado, United States
VA Puget Sound Health Care System, Seattle, Washington, United States
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Status: Recruiting
Last Changed: Mar 24, 2020
First Received: Dec 09, 2019
Disease(s): Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma
Intervention(s): Fludarabine, Melphalan, Total Body Irradiation
Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Allo HSCT Using RIC for Hematological Diseases
Status: Recruiting
Last Changed: Sep 25, 2019
First Received: Jan 21, 2016
Disease(s): Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
Intervention(s): Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Status: Recruiting
Last Changed: Dec 30, 2019
First Received: Oct 19, 2017
Disease(s): Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
Intervention(s): HSCT with TBI Regimen, HSCT with Non-TBI Regimen
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Status: Recruiting
Last Changed: Sep 25, 2019
First Received: Mar 30, 2016
Disease(s): Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Large-cell Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Marginal Zone B-cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-cell Lymphoma, Prolymphocytic Leukemia, Bone Marrow Failure Syndromes, Myeloproliferative Neoplasms/Myelofibrosis, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Leukemia or MDS in Aplasia, Relapsed T-Cell Lymphoma, Relapsed Multiple Myeloma, Plasma Cell Leukemia
Intervention(s): Fludarabine, Cyclophosphamide, MMF, Sirolimus, TBI, Umbilical cord blood cell infusion, ATG
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies
Status: Recruiting
Last Changed: Feb 17, 2020
First Received: Feb 06, 2019
Disease(s): Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, Richter Transformation Lymphoma, Burkitt Lymphoma, Lymphoplasmacytoid Lymphoma, T-cell Non-Hodgkin Lymphoma, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Waldenstrom Macroglobulinemia
Intervention(s): VLS-101 Schedule 1, VLS-101 Schedule 2, VLS-101 Schedule 3
Locations: City of Hope National Medical Center, Duarte, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States
university of Nebraska Medical Center, Omaha, Nebraska, United States
Northwell Health/CLL Research and Treatment Program, New Hyde Park, New York, United States
... and 6 other locations.
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Status: Recruiting
Last Changed: May 15, 2019
First Received: Sep 17, 2018
Disease(s): Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Lymphoplasmacytic Lymphoma
Intervention(s): Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI), Tacrolimus (Tac), Mycophenolate Mofetil (MMF), Granulocyte Colony-Stimulating Factor (G-CSF), Busulfan (BU), Melphalan, MGTA 456 Infusion
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Status: Recruiting
Last Changed: Jul 15, 2019
First Received: Dec 19, 2016
Disease(s): Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Lymphoma,Non-Hodgkin, Lymphoma, Hodgkin, Lymphoma, Follicular, Marginal Zone Lymphoma, Large Cell Lymphoma, Mantle-Cell Lymphoma, Gray Zone Lymphoma, Burkitt Lymphoma
Intervention(s): Bendamustine, Cyclophosphamide
Locations: The University of Arizona Cancer Center, Tucson, Arizona, United States
Phase 1 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Status: Recruiting
Last Changed: Mar 25, 2020
First Received: Sep 14, 2017
Disease(s): Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Intervention(s): ATA188, Placebo
Locations: Mayo Clinic, Scottsdale, Arizona, United States
The NeuroMedical Center Clinic, PC, Baton Rouge, Louisiana, United States
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
The University of Texas Health Science Center at Houston, Houston, Texas, United States
... and 4 other locations.
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Status: Recruiting
Last Changed: Feb 05, 2020
First Received: Feb 01, 2017
Disease(s): ALK-Positive Large B-Cell Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Human Herpesvirus 8-Positive Neoplastic Cells Present, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Intervention(s): Nivolumab, Varlilumab
Locations: Mayo Clinic Hospital, Phoenix, Arizona, United States
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Moffitt Cancer Center-International Plaza, Tampa, Florida, United States
Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States
... and 13 other locations.